Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (Journal for ImmunoTherapy of Cancer (2018) 6 (103) DOI: 10.1186/s40425-018-0412-0);Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Johnson, Daniel H ^a   Zobniw, Chrystia M ^b   Trinh, Van A ^b   Ma, Junsheng ^a   Bassett, Roland L ^a   Abdel Wahab, Noha ^a,b   Anderson, Jaime ^b   Davis, Jennifer E ^a   Joseph, Jocelyn ^b   Uemura, Marc ^a   Noman, Ali ^a   Abu Sbeih, Hamzah ^a   Yee, Cassian ^a   Amaria, Rodabe ^a   Patel, Sapna ^a   Tawbi, Hussein ^a   Glitza, Isabella C ^a   Davies, Michael A ^a   Wong, Michael K ^a   Woodman, Scott ^a   Hwu, Wen Jen ^a   Hwu, Patrick ^a   Wang, Yinghong ^a   Diab, Adi ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

Immune checkpoint inhibitors; Immune related enterocolitis; Infliximab

Indexed keywords

ATEZOLIZUMAB; DEXAMETHASONE; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; TICILIMUMAB; CORTICOSTEROID; GASTROINTESTINAL AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ENDOSCOPY; ENTEROCOLITIS; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUSCLE WEAKNESS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT FAILURE; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ENTEROCOLITIS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE;

EID: 85054779229     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0469-9     Document Type: Erratum

References (28)

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-56.
2. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13.
3. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19): 1856-1867.
4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33.
5. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-26.
6. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-42.
7. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
8. Lin R, Yellin MJ, Lowy I, et al. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis. Prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008; 26(suppl 20): abstr 9063.
9. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-55.
10. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
11. Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22(2):121-9.
12. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
13. Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-7.
14. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997;159:6276-82.
15. Braegger CP, Nicholls S, Murch SH, et al. TNF-α in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
16. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538.
17. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17.
18. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-90.
19. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J of Med. 2018;378(22):2093-104.
20. Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061-4.
21. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer center. J Clin Oncol. 2015;33:3193-8.
22. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785-92.
23. Snzol M, Ferrucci PF, Hogg D et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35(34):3815-22.
24. Kollias G, Kontoyiannis D, Douni E, Kassiotis G. The Role of TNF/TNFR in Organ-Specific and Systemic Autoimmunity: Implications for the Design of Optimized 'Anti-TNF' Therapies in Signal Transduction Pathways in Autoimmunity. Curr Dir Autoimmun. 2002;5:30-50.
25. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193(4):427-34.
26. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998;10(6):669-76.
27. Clark J, Vagenas P, Panesar M, Cope AP. What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis. 2005;64(suppl 4):iv70-6.
28. Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256